Drug intelligence / Profile preview

efudipine hydrochloride

Development stage: Unknown
Lead developer: Beijing Jialin Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Efudipine hydrochloride is a dihydropyridine calcium channel blocker (CCB) developed by Beijing Honghui Biopharmaceutical for the treatment of hypertension. It acts by inhibiting L-type voltage-gated calcium channels in vascular smooth muscle, which leads to vasodilation and a reduction in peripheral vascular resistance. The drug has been evaluated in Phase 1 clinical trials in China to assess its safety, pharmacokinetics, and pharmacodynamics in healthy volunteers, specifically focusing on its plasma concentration profiles and blood pressure-lowering effects.

Other names: efedipine hydrochlorideefudipine埃福地平盐酸盐

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on efudipine hydrochloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on efudipine hydrochloride.

Explore the full profile